Eli Lilly-Backed Aktis Jumps 24% After $318 Million US IPO

Aktis Oncology Inc. shares jumped 24% in their trading debut after the clinical-stage biotechnology company raised $317.7 million in an initial public offering.

Shares of the Boston-based firm closed at $22.40 per share on Friday in New York, versus an IPO price of $18 apiece. The offering of 17.65 million was marketed in a range of $16 to $18 each, and was increased from 11.8 million shares earlier in the week. The listing also drew interest from existing backer Eli Lilly & Co. for about $100 million in shares, according to an earlier filing.